Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409974PMC
http://dx.doi.org/10.1016/S2213-2600(21)00266-6DOI Listing

Publication Analysis

Top Keywords

imatinib covid-19
4
covid-19 hope
4
hope caution
4
imatinib
1
hope
1
caution
1

Similar Publications

Integrative analyses of mendelian randomization and bioinformatics reveal casual relationship and genetic links between COVID-19 and knee osteoarthritis.

BMC Med Genomics

January 2025

Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, China.

Background: Clinical and epidemiological analyses have found an association between coronavirus disease 2019 (COVID-19) and knee osteoarthritis (KOA). Infection with COVID-19 may increase the risk of developing KOA.

Objectives: This study aimed to investigate the potential causal relationship between COVID-19 and KOA using Mendelian randomization (MR) and to explore the underlying mechanisms through a systematic bioinformatics approach.

View Article and Find Full Text PDF

Evaluating imatinib in severe COVID-19: a systematic review and meta-analysis.

Trans R Soc Trop Med Hyg

November 2024

Departamento de Medicina Social, Universidade Federal do Espírito Santo, Vitória 29090-040, Brazil.

Background: Considering the potential antiviral and immunomodulatory properties of imatinib, this drug has been investigated in several studies as a potential treatment option for severe cases of COVID-19, given that treatment modalities available remain limited.

Objectives: To evaluate the benefits or otherwise of imatinib for COVID-19 in severely ill patients, we performed a systematic review of studies that tested the efficacy and the safety of imatinib for COVID-19 and executed a meta-analysis.

Methods: We searched Medline, Embase and Cochrane with the following search terms: 'coronavirus', 'SARS-Cov2', 'covid', 'covid-19' and 'imatinib'.

View Article and Find Full Text PDF

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by excessive proliferation of myeloid cells. The COVID-19 pandemic has raised concerns regarding the impact of SARS-CoV-2 on patients with malignancies, particularly those with CML. This study aimed to investigate the effects of SARS-CoV-2 proteins on CML cell viability and the protective role of vitamin K2 (VK2) in conjunction with imatinib.

View Article and Find Full Text PDF

Introduction: Inflammatory factors released during severe coronavirus disease-19 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are known to influence drug exposure, but data on the effect of mild infection are few. Here we describe for the first time an increase in plasma imatinib and norimatinib concentrations observed in a series of 5 patients treated with imatinib for gastrointestinal stromal tumor (GIST) after mild COVID-19.

Methods: The patients were undergoing routine therapeutic drug monitoring (TDM) and pharmacogenetic (PGx) analyses of polymorphisms in genes involved in imatinib metabolism and transport (, , , and ) when SARS-CoV-2 infection occurred.

View Article and Find Full Text PDF
Article Synopsis
  • Organoids are advanced models that replicate the structure and function of organs, initially developed from the small intestine, and now include various other organs like the liver and lungs.
  • This review highlights the lack of comprehensive research on gastrointestinal tract (GIT) organoids, emphasizing their role in studying diseases such as inflammatory bowel disease and drug screening for treatments.
  • GIT organoids have proven valuable in testing drug effects, understanding viral infections like Norovirus and SARS-CoV-2, assessing compound toxicity, and exploring immune responses and microbiome interactions, while also introducing cost-effective culture methods.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!